Trial Details Merck’s Deceptive Strategy

Vioxx Trial Details Deceptive Strategy.A Vioxx trial in Australia has shed new light on the questionable tactics Merck & Co. used to market the dangerous painkiller. The strategies, detailed in an article published by The New York Times, will not surprise anyone who has followed this blog’s Vioxx coverage.

Vioxx was approved for use in the U.S. in  1999, and quickly became a blockbuster for Merck, with annual sales of $2.5 billion. The Food & Drug Administration (FDA) ordered the painkiller off the market in 2004 after an analysis of patients using ‘Vioxx’ linked the defective drug to more than 27,000 heart attacks or sudden cardiac deaths in the U.S. from 1999 through 2003. ‘Vioxx’ was also recalled in more than 80 countries that year.

The Vioxx recall spawned thousands of product liability lawsuits

The Vioxx recall spawned thousands of product liability lawsuits. In 2007, Merck agreed to settle most U.S. ‘Vioxx’ claims for $4.85 billion. But the company is still defending lawsuits in other countries, including Australia.

We’ve already reported on one of the most shocking tactics used by Merck to push ‘Vioxx’ in Australia – the use of a fake medical journal. The journal, published by Elsevier, looked like  other peer-reviewed medical journals, but contained only reprinted or summarized articles – all of which presented Merck products, including ‘Vioxx’, in a favorable light.

some  It was presented to doctors as a real medical journal.

Australian trial has revealed that Vioxx sales

The New York Time  is also reporting that the Australian trial has revealed that ‘Vioxx’ sales reps in that country were given a training manual called the “Vioxx Objection Handling Module.” This manual schooled reps in methods of deflecting doctors’ questions about the drug’s side effects, and easing their concerns. According to The New York Times, Merck began distributing the manual in 2001 as studies began to emerge that pointed to the drug’s heart and stroke risks.

The Australian trial has also demonstrated how disillusioned doctors felt when they learned Merck had tried to obscure Vioxx’s safety issues. For example, in  an e-mail message dated Oct. 2, 2004,  Dr. James V. Bertouch, an Australian physician who had been a member of Merck’s arthritis advisory board, told  fellow board member that  he felt “like the proverbial mushroom” and asked colleagues how they felt being kept in the dark about ‘Vioxx’.

Need Legal Help Regarding Vioxx?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).